WATCH: attractive franchise, demanding valuation
H1 strong, Q2 weaker
Watch: Require repeat commercial cash
Home / Research / Neuland Laboratories Limited
WATCH: attractive franchise, demanding valuation
Issuer Q2 statutory results / presentation / analyst calculations
Issuer Q2 statutory results / presentation / analyst calculations
Issuer Q2 statutory results / presentation / analyst calculations
Issuer Q2 statutory results / presentation / analyst calculations
H1 strong, Q2 weaker
Watch: Require repeat commercial cash
Consolidated operating sales
Watch: Track cumulative revenue
Q1 strength offsets weaker Q2
Watch: Verify H2
Management business-mix disclosure
Watch: Track repeat volume
SAGE PRO Institutional Research | 16 November 2026 | Q2 FY2027 | NSE: NEULANDLAB
Key takeaways
Assess cumulative sales, cash and asset returns rather than extrapolating either Q1's peak or Q2's trough. The business is moving from ordinary generic API economics toward complex, customer-specific commercial manufacturing.
Reference ₹21,640, Sage PRO financial data quote observed 16 November 2026 around 16:31 IST (not an independently certified settlement price). Paid-up equity ₹12.9005 crore at ₹10 face value implies 1.29005 crore issued shares and equity value approximately ₹27,917 crore.
FY26 consolidated EPS ₹283.71 implies 76.3x; annualised H1 EPS ₹310.68 implies 69.7x, not a forecast. Our illustrative FY28 base EPS ₹418.27 at 50x gives ₹20,913. The company can grow strongly and still deliver modest stock returns if valuation normalises.
The 12–24 month stance improves with sustained commercial demand, healthy owner cash and demonstrable productive capacity returns, or a more favourable entry price.
Variant thesis: commercial CMS growth and the late-stage pipeline provide a credible route to higher earnings, while modular peptide manufacturing creates longer-duration optionality. The counter-thesis is customer concentration, variable shipment quantities, input inflation and idle new assets before customer qualification.
Management says H1 was broadly on plan and FY27/FY28 growth expectations remain intact, not a specific quantitative forecast in the reviewed excerpt. The fundamental thesis fails if scientific capability and new capital persistently do not translate into repeat commercial cash.
This original source-verified research uses the Q2 statutory filing, accepted presentation and call; independent full institutional QA remains outstanding.
Key takeaways
GDS supports scale and diversification, with different price and material-cost economics. CMS offers process-specific differentiation and qualification advantages; the customer still controls the drug, clinical outcome, launch and allocation. A qualified relationship can be sticky without being exclusive or indefinitely secure.
The September deck discloses 99 active CMS projects versus 98 a year earlier: 17 preclinical, 23 Phase I, 20 Phase II, 13 Phase III, seven pre-registration/registration and 19 commercial (nine APIs, ten intermediates). Prior-year Phase III was eight and commercial 18.
The stage progression is more meaningful than a nearly flat total count. Pre-registration may include second-source qualification for a marketed drug. Counts do not reveal commercial contract value, margin, clinical probability or launch timing.
A low-volume ophthalmic intermediate ordered intermittently and a large API programme are economically very different. Do not value each molecule equally.
| CMS management metrics | H1 FY26 | H1 FY27 |
|---|---|---|
| Commercial revenue, ₹cr | 411 | 639 |
| Development revenue, ₹cr | 32 | 41 |
| Total of disclosed categories, ₹cr | 443 | 680 |
These are management business-mix disclosures, not independently audited segment profits. The Q2 commercial amount was about ₹214 crore and development ₹32 crore. Management said five or six commercial molecules contributed revenue in Q2, with some smaller intermediates ordered only every few years.
The call indicated no new launch in the preceding two or three quarters; differing order quantities drove recent unevenness rather than a new launch spike followed by disappearance. This is a testable explanation, not assurance of future shipments.
Evaluate aggregate repeat demand, customer conversion, new awards and net attrition over a longer period.
The first peptide module at Unit I is commissioned. Management describes upstream solid/liquid-phase synthesis and downstream purification and isolation, including purification columns and lyophilisation or spray drying. Neuland aims to make finished peptide API, not merely fragments. Module 1 is designed around two projects currently progressing. Equipment size must match batch requirements; oversized columns or reactors can force uneconomic output. Additional modules are to be based on actual demand and project fit, not a generic market size. Development, process qualification and commercial supply are separate milestones. The reviewed evidence does not identify a specific GLP-1 award or undisclosed commercial peptide revenue.
The most important Q&A disclosure is that Neuland bears idle costs for general portfolio capacity, except where a customer-specific facility arrangement changes the economics. Management anticipates some idle time over 1–1.5 years.
Development billings exist but are small; PPQ (process performance qualification) or validation-related revenue is expected around six to nine months from the call. A commercial supply agreement depends on successful validation, customer progress and applicable regulatory milestones.
Modules 2–4 depend on occupancy and visible projects. Do not treat a commissioned facility as mature utilised capacity. Track validated batches, yield, throughput, committed orders, actual capital spend and cash.
Key takeaways
| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 | H1 FY27 | H1 FY26 | FY26 |
|---|---|---|---|---|---|---|
| Operating revenue | 449.66 | 641.58 | 514.27 | 1091.23 | 807.03 | 2022.99 |
| Other income | 7.50 | 8.49 | 1.80 | 15.99 | 9.66 | 30.17 |
| Total income | 457.15 | 650.07 | 516.07 | 1107.22 | 816.68 | 2053.15 |
| Materials + inventory change | 151.06 | 221.02 | 183.61 | 372.08 | 297.15 | 755.50 |
| Employee expense | 101.76 | 106.43 | 80.37 | 208.19 | 153.84 | 341.14 |
| Manufacturing expense | 57.80 | 47.94 | 45.96 | 105.74 | 85.33 | 191.61 |
| Other expense | 41.48 | 43.30 | 48.79 | 84.77 | 80.67 | 160.23 |
| Derived operating EBITDA | 97.56 | 222.89 | 155.55 | 320.45 | 190.03 | 574.50 |
| D&A | 28.77 | 26.56 | 22.54 | 55.33 | 42.73 | 91.74 |
| Finance cost | 7.31 | 6.97 | 5.37 | 14.28 | 9.95 | 23.95 |
| PBT | 68.98 | 197.85 | 129.44 | 266.83 | 147.01 | 488.98 |
| PAT | 51.63 | 147.67 | 96.85 | 199.30 | 110.75 | 364.00 |
| Basic/diluted EPS ₹ | 40.24 | 115.10 | 75.49 | 155.34 | 86.32 | 283.71 |
Q2 operating EBITDA ₹97.56 crore equals operating sales less materials/inventory, employee, manufacturing and other expenses. Add other income ₹7.50 crore and subtract D&A ₹28.77 crore and interest ₹7.31 crore to reach PBT ₹68.98 crore; tax ₹17.35 crore gives PAT ₹51.63 crore.
The issuer's standalone Q2 EBITDA ₹104.55 crore, margin 22.9% of total income, and PAT ₹51.13 crore are distinct. H1 standalone EBITDA ₹335.62 crore at 30.3% versus ₹199.07 crore/24.4%. Consolidated derived operating EBITDA Q2 ₹97.56 crore (21.7%) versus ₹155.55 crore (30.2%); H1 ₹320.45 crore (29.4%) vs ₹190.03 crore (23.5%).
Both measures show strong H1 and weaker Q2; maintain consistent scope and denominators.
Sequential sales fell ₹191.92 crore. Materials/inventory costs fell ₹69.96 crore, personnel ₹4.67 crore, manufacturing expense rose ₹9.86 crore and other expense fell ₹1.82 crore. EBITDA fell ₹125.33 crore, about 65% of lost sales. This is fixed-resource and mix deleverage, not a permanent decremental margin. YoY sales fell ₹64.62 crore while employee and manufacturing expenses rose ₹21.39 crore and ₹11.85 crore; materials/inventory fell ₹32.55 crore and other expense fell ₹7.31 crore. EBITDA declined ₹57.99 crore. Q2 inventory-change credit ₹64.73 crore versus ₹44.03 crore prior year and ₹7.75 crore Q1. Combined material/inventory cost 33.6% of sales versus 35.7% prior year. The improvement did not offset lower revenue and overhead; inventory credits are not necessarily cash savings.
H1 sales rose ₹284.21 crore (+35.2%), EBITDA ₹130.42 crore (+68.6%), PAT ₹88.54 crore (+79.9%). Tax ₹67.53 crore on PBT ₹266.83 crore gives 25.3%, a reasonable forward assumption. Employee costs increased ₹54.35 crore, manufacturing ₹20.41 crore and D&A ₹12.60 crore.
Strong H1 absorption supports the franchise but Q2 shows the cost of underutilisation. FY26 derived operating EBITDA ₹574.50 crore (28.4%), EBIT ₹482.76 crore and PAT ₹364 crore. H1 other income ₹15.99 crore versus ₹9.66 crore is excluded from core operating margin.
FY26 operating sales ₹2,022.99 crore, H2 ₹1,215.96 crore. FY27 H1 ₹1,091.23 crore. Flat FY27 requires ₹931.75 crore H2 (-23.4% YoY); 20% annual growth requires ₹1,336.35 crore (+9.9%); 30% requires ₹1,538.65 crore (+26.5%).
Repeating Q2 twice produces annual sales ₹1,990.55 crore (-1.6%). The strong first half does not establish a specific full-year growth rate. These analyst hurdles are reproducible and should be updated after Q3; do not mistake the issuer's qualitative growth expectation for guidance on a precise percentage.
Key takeaways
Taxes paid ₹72.86 crore. CFO/PAT ~181%; strong underlying earnings and collections both contributed, but a large release from high opening receivables should not be extrapolated as perpetual cash. The proper owner-return test uses rolling operating cash, working capital and productive asset investment.
| H1 consolidated cash flow ₹cr | FY27 | FY26 |
|---|---|---|
| Operating cash before working capital | 319.52 | 198.42 |
| Inventory movement | -41.81 | -162.14 |
| Receivables movement | 246.09 | -123.19 |
| Payables movement | -58.74 | 34.05 |
| Cash before taxes | 434.42 | 3.18 |
| Tax paid | -72.86 | -39.92 |
| CFO | 361.56 | -36.75 |
| Physical capital purchases | 260.60 | 170.75 |
| CFO less capital purchases | 100.96 | -207.50 |
September assets ₹3,029.56 crore vs March ₹2,930.14 crore; equity ₹2,029.71 crore vs ₹1,874.47 crore. PPE ₹901.62 crore vs ₹793.42 crore; CWIP ₹284.30 crore vs ₹209.50 crore; goodwill ₹279.46 crore unchanged; ROU ₹92.58 crore. PPE+CWIP rose ₹183 crore to ₹1,185.92 crore. Inventory ₹552.10 crore vs ₹510.29 crore, receivables ₹294.30 vs ₹541.35 crore, payables ₹208.62 vs ₹269.14 crore. Narrow trade working capital fell ₹782.50 to ₹637.78 crore. Management standalone working capital ₹628.5 crore and days 104 vs 155 prior H1, but 84 in Q1. Definitions differ; collection improved while inventory and supplier payments still require capital. Ending receivables roughly 49 days of annualised H1 sales versus ~98 days at March/FY26 sales, not contractual DSO.
Borrowings ₹239.20 crore vs ₹196.61 crore March; lease liabilities ₹103.10 crore. Cash equivalents ₹53.66 crore plus other bank balances ₹396.78 crore = ₹450.44 crore; less borrowings gives broad net cash ₹211.24 crore before restrictions and leases.
Management standalone net cash ₹208 crore versus ₹308.5 crore Q1 and ₹156.8 crore March. Measures are close, not identical. Narrow debt less cash ₹185.54 crore. Current assets ₹1,389.85 crore/current liabilities ₹618.58 crore = 2.25x vs 2.09x March.
Other bank balances require unrestricted liquidity reconciliation. Do not add net cash to an equity earnings valuation that already includes financial income.
Module 1 commissioned, Genome Valley process R&D expected fully operational by early next year, ~134 acres acquired at Kakinada for long-term capacity. The November board separately approved ₹47.1 crore including GST and related expense for six acres at Domadugu through internal accruals; no capacity or commencement date disclosed. Land purchase, construction, qualification, PPQ, customer orders and collected cash are separate milestones. Management indicated Kakinada could be slowed if commercial demand weakens; later peptide modules depend on occupancy and project visibility. Cash-rich funding is helpful but no guarantee of incremental return.
An illustrative ₹300 crore productive investment at 15% after-tax return needs ₹45 crore NOPAT or ₹60 crore EBIT at 25% tax. With ₹20–30 crore incremental D&A, ₹80–90 crore EBITDA requires ₹267–300 crore annual sales at 30% operating margin.
Not a disclosed project cost or forecast. FY26 EBIT ₹482.76 crore / September PPE+CWIP ₹1,185.92 crore is a rough 40.7% pre-tax asset-return proxy; annualised H1 EBIT ₹530.24 crore gives 44.7%. Neither is full ROCE because working capital, goodwill, leases, average capital and financial assets differ.
Historical asset absorption is strong; idle peptide assets and land can depress future return until customer output follows.
Key takeaways
RFP activity described as strongest to date and large-pharma traction improve opportunity but are not booked sales. Diversification is demonstrated through repeat revenue from new customers.
Key takeaways
FY26 derived EBITDA ₹574.50 crore implies 48.9x narrow EV/EBITDA; not a full comparable EV. Model 1.30 crore shares, consolidated earnings, operating margin and explicit D&A, interest and tax assumptions.
| FY28 analyst scenario (₹cr except EPS/price) | Bear | Base | Bull |
|---|---|---|---|
| Operating sales | 2300 | 3000 | 3800 |
| Operating EBITDA margin | 21% | 30% | 34% |
| Operating EBITDA | 483 | 900 | 1292 |
| Other income | 25 | 30 | 35 |
| D&A | 150 | 170 | 190 |
| Finance cost | 35 | 35 | 40 |
| PBT | 323 | 725 | 1097 |
| PAT at 25% tax | 242.25 | 543.75 | 822.75 |
| EPS on 1.30cr shares | 186.35 | 418.27 | 632.88 |
| Terminal P/E assumption | 35x | 50x | 60x |
| Indicative price ₹ | 6522 | 20913 | 37973 |
| Change vs reference | -70% | -3% | +75% |
Bear assumes slower commercial deliveries, underutilised new assets and margin compression. Base assumes FY26–FY28 sales CAGR ~21.8%, margin 30% near H1, and higher D&A. Bull assumes ~37% sales CAGR, 34% margin and successful customer conversion.
These are independent analyst cases, not guidance, consensus or probability-weighted price targets; dividends and discounting excluded. Base PAT ~₹544 crore is 49% above FY26 yet indicative price below reference at 50x.
At 40x base EPS gives ₹16,731, at 60x ₹25,096. Strong business growth alone is insufficient at a premium valuation.
Reverse valuation at 50x: ₹21,640 requires EPS ₹432.80, PAT ₹562.64 crore on 1.30 crore shares. At 25% tax PBT ₹750.19 crore. Add D&A ₹170 crore, interest ₹35 crore and subtract other income ₹30 crore: EBITDA needed ₹925.19 crore.
At 30% margin sales ₹3,084 crore, ~23.5% CAGR from FY26 over two years. At 25% margin required sales ₹3,701 crore; at 35% ₹2,643 crore. For 20% price upside at 50x, EPS ₹519.36, PAT ₹675.17 crore, PBT ₹900.23 crore, EBITDA ₹1,075.23 crore and sales ₹3,584 crore at 30%.
A lower entry price changes the required growth without changing business quality.
Sensitivity: EPS ₹300 at 35x/50x/60x gives ₹10,500/15,000/18,000; ₹450 EPS gives ₹15,750/22,500/27,000; ₹600 gives ₹21,000/30,000/36,000. Each additional ₹100 crore revenue at 30% incremental EBITDA and 25% tax adds ₹22.5 crore PAT before extra D&A/interest, ~₹17.31 EPS or ₹865 at 50x.
Not a linear forecast for a large capacity expansion. A full owner-cash DCF needs project-specific capex, clinical and qualification probabilities, future working capital, tax and reinvestment. H1 collection release is not perpetual cash yield.
No unverified peer multiple or precise DCF target is asserted.
Catalysts: cumulative H2 CMS deliveries, net late-stage and commercial conversion, diversification, PPQ-related peptide revenue and subsequent supply, Genome Valley operation, healthy normalised operating margin and rolling cash. Risks: customer/molecule concentration, shipment timing, clinical failure and sourcing shifts, patent/competition, raw materials/freight, quality and regulatory compliance, idle peptide cost, excessive land/plant investment, working-capital reversals, valuation compression. Follow official inspection outcomes; lack of adverse news is not proof of compliance.
Track operating EBITDA, CFO before working capital, physical capital purchases, debt/deposits, commercial contribution and EPS. A sustained gap between scientific capability and owner cash invalidates the constructive thesis.
Revisit WATCH on stronger evidence or a better entry price.
Original source ledger.
Key takeaways
Board land approval ₹47.1 crore.
S2. Q2 FY27 investor presentation, 3 November: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4e485402-d792-49dd-810e-4e0141fd33ed.pdf . Canonical 69651, current semantic ACCEPT. Pages 6–11 for financial highlights, CMS funnel, mix and operating metrics; overview for capability data.
S3. Call held 3 November, filed 6 November: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=abfcdee9-1e06-45b7-a6ab-8d7490dfebef.pdf . Canonical 76405, current semantic ACCEPT. Q&A pp. 5–10 peptide idle costs, PPQ timing, shipment pattern, concentration and patent commentary.
S4. Issuer Q2 release: . S5. Sage PRO financial data quote ₹21,640 observed 16 November 2026 ~16:31 IST; refresh before investing.
Independent full institutional QA, original page-image parity, quantified peer valuation, complete owner-cash DCF and project-level return/patent reconciliation remain outstanding. Forward inputs and thresholds are analyst assumptions. This is a source-verified original longform, not a certified full-QA edition.
Issuer Q2 statutory results / presentation / analyst calculations
Issuer Q2 statutory results / presentation / analyst calculations
Issuer Q2 statutory results / presentation / analyst calculations
Issuer Q2 statutory results / presentation / analyst calculations
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.